During a recent Congressional hearing, Rep. Colin Allred revealed that the Department of Veterans Affairs (“VA”) has closely been following studies on the therapeutic benefits of psychedelic substances such as MDMA for veterans. The meeting, which was held last month before the House Veterans’ Affairs Committee, focused on innovative approaches to deal with suicide prevention in veterans.
Officials had asked for an update on the study evaluating the use of psychedelic substances for the treatment of PTSD in military veterans, noting that there were good results from prior research on how psychedelic substances could help alleviate the mental health struggles of veterans. Allred gave the example of a study published in the “Nature Medicine” journal in May 2021 that reported on the use of MDMA as a therapeutic option for severe post-traumatic stress disorder.
Lisa Brenner of Veterans Affairs, who also serves as director of the Rocky Mountain Mental Illness Research Education and Clinical Centre for Suicide Prevention, stated that the department was aware of these studies and had been tracking some studies closely, adding that the agency was anticipating the results of some trials that were currently being conducted.
Allred asked Brenner if there were any additional approvals the department would require from Congress to carry on with its research on psychedelics. Brenner replied that while it was a complicated issue, she’d report back with any additional information on the matter.
Recently, Rep. Dan Crenshaw, who is also a veteran, tried to add an amendment to the 2022 National Defence Authorization Act that would require the Department of Defense carry out a clinical trial on the therapeutic benefits of psychedelic substances for military members with post-traumatic stress disorder and chronic pain. However, the amendment wasn’t voted on because it was blocked by the House Rules Committee.
In addition, Rep. Lou Correa introduced an amendment on cannabis research that he had initially wanted to include in the department’s spending bill. The amendment would direct the head of Veterans Affairs to conduct a randomized, double-blind, controlled clinical trial on the effects of medical-grade marijuana on the health outcomes of veterans who had been diagnosed with PTSD and chronic pain. However, this initiative was also withdrawn before it was considered on the floor.
A federal report released in 2020 directed that the executive branch and Congress promote research into the therapeutic potential of psychedelic substances including MDMA and magic mushrooms as well as cannabis.
Meanwhile, clinics administering ketamine treatments already exist in some U.S. jurisdictions while companies such as Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) operate extensive networks of such clinics in Canada.
NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE…
The new FDA voucher program aims to speed approval of drugs aligned with national health…
The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…
The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…
Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined…
Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network…